| Bioactivity | HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage[1]. |
| Target | EC50: 0.005 ± 0.005 μM (HCV) |
| Name | HCV-IN-37 |
| CAS | 2425804-98-2 |
| Formula | C31H35F2N5 |
| Molar Mass | 515.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Y, et al. Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors. J Med Chem. 2022 Feb 10;65(3):2107-2121. |
HCV-IN-37
CAS: 2425804-98-2 F: C31H35F2N5 W: 515.64
HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.